Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
111.5 DKK | -0.96% | -0.49% | +5.99% |
04-12 | Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest | DJ |
04-11 | U.S. Futures Down, European Stocks Mixed | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 75.59 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.99% | 4.3B | B | ||
-3.72% | 184B | C+ | ||
-2.60% | 107B | C | ||
-3.79% | 67.78B | A | ||
+2.66% | 50.66B | B- | ||
+16.39% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+1.38% | 26.3B | B | ||
+1.52% | 26.04B | A- | ||
-1.17% | 24.71B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMBU B Stock
- Ratings Ambu A/S